| 2026-08-11 | Press release | Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability |
| 2026-07-31 | Press release | Organon Announces Quarterly Dividend |
| 2026-07-24 | Press release | New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improveme |
| 2026-07-16 | Press release | July 16, 2026 |
| 2026-07-07 | Press release | July 7, 2026 |
| 2026-06-22 | Press release | June 22, 2026 |
| 2026-06-10 | Press release | June 10, 2026Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab- |
| 2026-05-15 | Press release | May 15, 2026Organon to Present New Research on Access and Value at ISPOR 2026 |
| 2026-04-30 | Press release | Organon Reports Results for the First Quarter Ended March 31, 2026 |
| 2026-04-29 | Press release | European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA |
| 2026-04-29 | Press release | April 29, 2026Organon Cancels First Quarter Earnings Call |
| 2026-04-26 | Press release | April 26, 2026Organon’s Sale to Sun Pharma |
| 2026-04-16 | Press release | Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026 |
| 2026-04-15 | Press release | Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidel |
| 2026-03-27 | Press release | Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin |
| 2026-02-27 | Press release | New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient- |
| 2026-02-23 | Press release | Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device |
| 2026-02-12 | Press release | Organon Q4 2025 Financial Results |
| 2026-02-11 | Earnings deck | Organon Q4 2025 Earnings Presentation |
| 2026-01-29 | Press release | Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026 |
| 2026-01-28 | Press release | Organon Completes Divestiture of JADA® System to Laborie |
| 2026-01-16 | Press release | Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Us |
| 2026-01-08 | Press release | Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo<sup>®</sup> in France, Denmark, Iceland, |
| 2025-11-25 | Press release | Organon To Present at the Piper Sandler 37th Annual Healthcare Conference |
| 2025-11-17 | Press release | Henlius and Organon Announce US FDA Approval of POHERDY<sup>®</sup> (pertuzumab-dpzb), the First PERJETA (pertuzumab) Bi |
| 2025-11-10 | Press release | Organon Reports Results for the Third Quarter Ended September 30, 2025 |
| 2025-11-08 | Press release | New Data Show Early and Consistent Response to VTAMA<sup>®</sup> (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic |
| 2025-11-07 | Press release | Organon Announces Agreement to Divest its JADA<sup>®</sup> System for Up to $465 Million to Laborie |
| 2025-11-06 | Press release | Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025 |
| 2025-09-19 | Press release | European Commission (EC) Approves Henlius and Organon’s BILDYOS<sup>®</sup> (denosumab) and BILPREVDA<sup>®</sup> (denos |
| 2025-09-02 | Press release | US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS<sup>®</sup> (denosumab-nxxp) and BILPREVDA< |
| 2025-08-05 | Press release | Organon Reports Results for the Second Quarter Ended June 30, 2025 |
| 2025-07-22 | Press release | Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025 |
| 2025-07-07 | Press release | Organon’s VTAMA<sup>®</sup> (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology |
| 2025-07-02 | Press release | Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Relate |
| 2025-06-12 | Press release | Organon and Evvy Announce Collaboration to Expand Access of XACIATO<sup>®</sup> (clindamycin phosphate) vaginal gel 2%, |
| 2025-05-27 | Press release | US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (ada |
| 2025-05-01 | Press release | Organon Reports Results for the First Quarter Ended March 31, 2025 |
| 2025-04-15 | Press release | Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 |
| 2025-04-15 | Press release | Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors |